二甲双胍与肠道中降解黏蛋白的Akkermania muciniphila及多种产短链脂肪酸微生物相对丰度升高相关
在哥伦比亚社区成人中,比较糖尿病用或不用二甲双胍者与无糖尿病者的肠道菌群。糖尿病与菌群关联受二甲双胍使用修饰:用二甲双胍者Akkermania muciniphila及多种产短链脂肪酸菌相对丰度高于无糖尿病者;不用二甲双胍者某些菌丰度不同。结果支持二甲双胍改变肠道菌群组成的假说。
要点
- 糖尿病与肠道菌群的关联受二甲双胍使用修饰。
- 用二甲双胍的糖尿病者Akkermania muciniphila及多种产短链脂肪酸菌相对丰度高于无糖尿病者。
- 不用二甲双胍的糖尿病者Clostridiaceae 02d06和特定Prevotella操作分类单元丰度高于无糖尿病者,Enterococcus casseliflavus丰度低于无糖尿病者。
核心结论
- 结果支持二甲双胍通过富集降解黏蛋白的Akkermania muciniphila及多种产短链脂肪酸菌来改变肠道菌群组成的假说。
- 未来需研究确定这些菌群变化是否介导二甲双胍的降糖和抗炎特性。
研究设计与样本
- 参与者选自一个459人的较大队列。
- 本分析纳入28名糖尿病患者(其中14名服用二甲双胍)和84名无糖尿病者,无糖尿病者按性别、年龄和BMI与糖尿病者3比1匹配。
- 测量人口学信息、人体测量学和血液生化指标,并采集粪便样本进行16S rRNA基因测序以分析肠道菌群组成和结构。
主要发现
- 与无糖尿病者相比,服用二甲双胍的糖尿病者Akkermania muciniphila(一种以降解黏蛋白著称的微生物)及多种以产短链脂肪酸著称的肠道菌相对丰度更高,包括Butyrivibrio、Bifidobacterium bifidum、Megasphaera和一个Prevotella操作分类单元。
- 与无糖尿病者相比,不服用二甲双胍的糖尿病者Clostridiaceae 02d06和一个特定Prevotella操作分类单元相对丰度更高,Enterococcus casseliflavus丰度更低。
局限性
- 未来需研究确定这些菌群变化是否介导二甲双胍的降糖和抗炎特性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recent studies suggest the beneficial effects of metformin on glucose metabolism may be microbially mediated. We examined the association of type 2 diabetes, metformin, and gut microbiota in community-dwelling Colombian adults. On the basis of previous research, we hypothesized that metformin is associated with higher levels of short-chain fatty acid (SCFA)-producing and mucin-degrading microbiota. RESEARCH DESIGN AND METHODS: Participants were selected from a larger cohort of 459 participants. The present analyses focus on the 28 participants diagnosed with diabetes-14 taking metformin- and the 84 participants without diabetes who were matched (3-to-1) to participants with diabetes by sex, age, and BMI. We measured demographic information, anthropometry, and blood biochemical parameters and collected fecal samples from which we performed 16S rRNA gene sequencing to analyze the composition and structure of the gut microbiota. RESULTS: We found an association between diabetes and gut microbiota that was modified by metformin use. Compared with participants without diabetes, participants with diabetes taking metformin had higher relative abundance of Akkermansia muciniphila, a microbiota known for mucin degradation, and several gut microbiota known for production of SCFAs, including Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and an operational taxonomic unit of Prevotella. In contrast, compared with participants without diabetes, participants with diabetes not taking metformin had higher relative abundance of Clostridiaceae 02d06 and a distinct operational taxonomic unit of Prevotella and a lower abundance of Enterococcus casseliflavus. CONCLUSIONS: Our results support the hypothesis that metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several SCFA-producing microbiota. Future studies are needed to determine if these shifts mediate metformin's glycemic and anti-inflammatory properties.
引用
- de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2016. PMID: 27999002. doi:10.2337/dc16-1324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。